Case Study 1 — Theo's Lipid Panel: What the Numbers Were Actually Saying

A clinical case. Theo Vasquez is an illustrative composite; the lipid physiology and the clinical reasoning are not.

Setup

Theo brought the folder in Chapter 1 and the food diary in Chapter 4. In Chapter 9 he brought something more useful than either: his actual bloods.

He had spent eight years, five diets, and two highlighter colours on the saturated fat question.

His saturated fat intake is not what these numbers are telling us.

Reading the panel properly

Most people — and a fair number of clinicians pressed for time — read a lipid panel by looking at LDL, and Theo's LDL is only modestly above optimal. On that reading he looks like a borderline case where you'd discuss diet and recheck in a year.

Read the whole panel together and a different picture appears.

The triad

Three findings travel together here and they are the signature of one underlying process:

• Triglycerides elevated (186)
• HDL low (38)
• Small, dense LDL particles — not measured directly on a standard panel, but strongly implied by the first two

Add elevated fasting glucose, HbA1c in the prediabetes range, elevated blood pressure, and central adiposity, and you have the recognizable pattern of insulin resistance and metabolic dysfunction — the cluster Chapter 26 covers properly.

This is not a saturated fat problem. It is a problem of energy surplus, adiposity, physical inactivity, alcohol, and refined carbohydrate — and the lipid abnormalities are downstream of it.

Why the LDL number understates his risk

Here's where §9.10 earns its place.

Theo's LDL-C is 131 — cholesterol cargo. But in the presence of elevated triglycerides and low HDL, LDL particles tend to be smaller and denser, which means more particles are required to carry the same cholesterol.

More particles means more ApoB, and per the artery-wall diagram in §9.10, more particles means more encounters with the endothelium and more retention events.

So his ApoB is likely disproportionately high relative to his LDL-C — meaning a standard panel is under-representing his actual atherogenic burden. We ordered ApoB. It came back elevated relative to what his LDL-C alone would have predicted.

This is the practical case for ApoB in one paragraph. For a person with a clean metabolic picture, LDL-C and ApoB largely agree and the extra test adds little. For a person with high triglycerides and low HDL — which describes a very large number of people — they diverge, and the divergence is in the dangerous direction. The test is inexpensive. It is not routine in many settings. It is worth asking for.

And the triglyceride number is telling you about alcohol and carbohydrate

Elevated triglycerides in this pattern are driven substantially by:

• Energy surplus — Theo is +490 kcal/day
• Alcohol — 27 g ethanol daily; alcohol raises triglycerides reliably and dose-dependently (Chapter 12)
• Refined carbohydrate and fructose — which drive hepatic triglyceride synthesis (Chapter 18)
• Adiposity and insulin resistance — the underlying driver

Not one of those four is saturated fat.

The conversation

I put the panel in front of him and asked what he thought the biggest problem was.

He pointed at LDL. Everyone does. It's the one with a name they recognize.

So I covered the LDL number with my thumb and asked him to read the rest — triglycerides, HDL, glucose, A1c, blood pressure, waist.

He said: "That's… that all looks like one thing."

Yes. It is all one thing. And the one thing is not butter.

Then I said the sentence that mattered:

"You've spent eight years on the least important variable on this page. Not because it doesn't matter — it matters a bit. Because everything else on here matters more, and nobody was arguing about those, so nobody wrote articles about them for you to print."

That's Chapter 1's media argument, arriving in a clinical form. The variables that generate content are not the variables that generate risk, and a careful person reading carefully will end up optimizing whatever the argument happens to be about.

What we actually changed

Nothing in this list is a fat intervention, except the cooking oil, which is nearly free.

Nine months later:

The triglycerides moved most and moved fastest — they usually do, because they're the most responsive to alcohol and energy balance. The A1c dropped out of the prediabetes range. And his LDL came down by twelve points, some of which is the olive oil and most of which is the seven kilograms.

Analysis

1. A lipid panel is a pattern, not a list. Reading LDL alone missed the entire story. Triglycerides + low HDL + central adiposity + rising glucose is a recognizable syndrome with a single upstream cause, and treating it as four separate numbers leads to four wrong interventions.

2. The panel understates risk in exactly the people who most need it not to. High triglycerides and low HDL imply small dense particles, which means high ApoB relative to LDL-C. The standard test is least accurate in the metabolically unhealthy — which is a genuinely awkward property for a screening tool.

3. Theo optimized the argued-about variable, not the important one. Eight years on saturated fat while his alcohol, fiber, energy balance, and activity went unexamined. That is the predictable output of getting your nutrition information from places that generate content, and it's not his fault.

4. The most effective intervention on a lipid panel is frequently not a lipid intervention. Alcohol, energy balance, fiber, and movement did more for Theo's cholesterol than any fat swap could have. This generalizes: the lever is often upstream of the number.

5. And a limit worth stating. ⚠️ Theo's numbers responded well to lifestyle change. Many people's don't, or don't enough — because of genetics, familial hypercholesterolemia, Lp(a), or simply because the effect size of diet on LDL is modest. Statins and related drugs move LDL far more than food does, and their outcome evidence is among the strongest in medicine. A nutrition book that implied otherwise would be doing harm. If your numbers don't respond, that is a medication conversation, not a failure of willpower.

Discussion Questions

1. I covered the LDL number with my thumb to make Theo read the rest. Why did that work better than explaining it? What does that suggest about how to present a panel?

2. ApoB is inexpensive and not routine. Given that it diverges most from LDL-C in the metabolically unhealthy, make the case for routine ApoB testing. Then make the case against — cost, capacity, and what would be displaced.

3. Theo spent eight years on saturated fat. Whose failure is that? Consider the media (Ch 1), his previous clinicians, and the structure of what gets argued about publicly.

4. Seven kilograms of weight loss did more for his LDL than the cooking oil swap. Does that make the cooking oil swap pointless? Consider effect size, cost, and durability together.

5. The analysis ends with a limit — that many people's numbers won't respond adequately to diet. How do you deliver that without either discouraging dietary change or overselling medication?

Your Turn

If you have had a lipid panel in the last two years, get it out.

Don't look at LDL first. Instead:

1. Triglycerides — elevated?
2. HDL — low?
3. The triglyceride : HDL ratio — divide one by the other
4. Fasting glucose and HbA1c if you have them
5. Waist circumference and blood pressure

Then look at LDL, last.

Do those markers look like separate findings, or like one thing? For a great many people they look like one thing, and the one thing is metabolic rather than dietary-fat-related.

Then ask the question this chapter is really about: if you were to change one item in your diet based on this panel, would it be your saturated fat intake — or would it be something you haven't been arguing about with anyone?

⚠️ And take the panel to a physician rather than to a book. This exercise is about learning to read what you're looking at, not about self-managing cardiovascular risk.